Convergent imaging and genetic signatures of gray matter atrophy in Parkinson's disease.

NeuroimageJun 23, 2026 (epub)
Clinical ResearchNeurologyMedical Genetics

Yingying Xie, Zihe Dong, Yurong Jiang et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined gray matter volume (GMV) abnormalities in Parkinson's disease (PD) by integrating neuroimaging data from 3,212 PD patients and 2,056 controls. The study identified 12 significant SNPs linked to GMV atrophy and revealed shared genetic pathways, enhancing understanding of neurodegenerative mechanisms in PD.

Key findings

  • Identified robust patterns of GMV reduction in PD patients compared to controls.
  • Discovered 12 significant SNPs associated with PD-related GMV atrophy.
  • Found 22 SNPs linked to both PD risk and GMV reduction.
  • Highlighted pathways involved in clathrin-mediated endocytosis and synaptic vesicle recycling.

Why it matters

Understanding the genetic underpinnings of gray matter atrophy in Parkinson's disease can inform future research and potential therapeutic strategies, ultimately improving patient outcomes and management of the disease.

Source

PubMed · PMID 42336304

Published in Neuroimage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.